Fenebrutinib HCl

• CAT Number: I027390
• CAS Number: 2128304-54-9
• Molecular Formula: C37H45ClN8O4
• Molecular Weight: 701.27
• Purity: 98%
• Synonyms: GDC-0853; GDC 0853; GDC0853; RG-7845; RG7845; RG 7845; Fenebrutinib HCl; Fenebrutinib hydrochloride
• Solubility: Soluble in DMSO
• Appearance: White to off-white solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: 10-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-4,4-dimethyl-1,10-diazatricyclo[6.4.0.02,6]dodeca-2(6),7-dien-9-one;hydrochloride
• InChI: InChI=1S/C37H44N8O4.ClH/c1-23-18-42(27-21-49-22-27)9-10-43(23)26-5-6-33(39-17-26)40-30-13-25(19-41(4)35(30)47)28-7-8-38-34(29(28)20-46)45-12-11-44-31(36(45)48)14-24-15-37(2,3)16-32(24)44;/h5-8,13-14,17,19,23,27,46H,9-12,15-16,18,20-22H2,1-4H3,(H,39,40);1H/t23-;/m0./s1
• InChIKey: UFNQEETXQCTBNF-BQAIUKQQSA-N
• SMILES: C[C@H]1CN(CCN1C2=CN=C(C=C2)NC3=CC(=CN(C3=O)C)C4=C(C(=NC=C4)N5CCN6C7=C(CC(C7)(C)C)C=C6C5=O)CO)C8COC8.Cl

Fenebrutinib HCl（Cat No.:I027390）is a selective inhibitor of Bruton’s tyrosine kinase (BTK), an enzyme critical to the activation of B-cells and the immune response. By inhibiting BTK, fenebrutinib blocks signaling pathways involved in autoimmune diseases, such as rheumatoid arthritis, lupus, and multiple sclerosis, as well as certain B-cell malignancies like chronic lymphocytic leukemia (CLL). Fenebrutinib HCl has shown promise in clinical trials for treating these conditions by modulating immune responses and reducing inflammation. Its targeted action on BTK offers potential advantages in treating autoimmune disorders and hematologic cancers with fewer side effects compared to traditional therapies.